Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices

The programmed death-1 inhibitor pembrolizumab has demonstrated efficacy and safety in clinical trials for treating advanced (unresectable/metastatic) melanoma. We investigated the real-world utilization of pembrolizumab and associated patient outcomes for advanced melanoma in US community oncology...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Immunother
Päätekijät: Cowey, C. Lance, Liu, Frank Xiaoqing, Black-Shinn, Jenny, Stevinson, Kendall, Boyd, Marley, Frytak, Jennifer R., Ebbinghaus, Scot W.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Lippincott Williams & Wilkins 2018
Aiheet:
Clinical Studies
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5811239/
https://ncbi.nlm.nih.gov/pubmed/29252916
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0000000000000204
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia